LLY

Pre-market strong earnings report, up 5%

This quarter

Revenue of 22.974 billion, exceeding the expected 20.725 billion, a year-on-year increase of 48%;

Earnings per share of 8.38, exceeding the expected 6.58, a year-on-year increase of 33%;

Among them, oral weight-loss drug sales were 98 million, slightly below the expected 103 million

Raised full-year 2026 guidance

Revenue raised from 82-85 billion to 85-87 billion;

Profit margin raised from 47.0%-48.5% to 49.0%-50.5%

Technical aspect

The stock price is oscillating at high levels, with little resistance above. Breaking through 1190 points to new highs, and future trends also look for continuous new highs.

If there is a pullback, especially below 1000, it would be a good opportunity to enter the market

Fundamental aspect

As of yesterday's closing price, it has risen 4.17% year-to-date

The current pre-market price is around 1170, not particularly expensive. The target price of 1400 for this year needs to be raised 📈

The magnitude of the raise is pending, as data has not yet been updated

Eli Lilly is a leading medical company in the US, with a current market cap of 1.05 trillion, ranked 10th in the S&P.

I have held it since last year as a defensive allocation. Currently, the returns are substantial, and it has grown into my third-largest holding. I will continue to hold it in the future